The novel antitumor antibiotic, trioxacarcin C, was studied for antitumor activities against murine tumor systems. When mice with i.p.-inoculated B16 melanoma were given intraperitoneal injections of trioxacarcin C, the maximal T/C% was 164 by successive administration of 0.125 mg/kg/day (day 1 -10). It also gave the prolongation of life span of mice bearing i.p. P388 leukemia (T/C 141 %) by i.p. injection for 10 days, and inhibited the growth of sarcoma 180 (T/C 42%) and Lewis lung carcinoma implanted s.c. (T/C 23 %) by i.v. administration for 6 or 7 days. It inhibited the growth of P388 leukemia cells in vitro and showed significant inhibition on the colony formation of HeLa S3 cells. DNA and RNA synthesis were more strongly inhibited than protein synthesis by trioxacarcin C. Also, it induced strand scission of PM-2 DNA without reducing agents or metals. It did not effect the number of white blood cells and blood urea nitrogen value of the peripheral blood.
murine tumor systems. When mice with i.p.-inoculated B16 melanoma were given intraperitoneal injections of trioxacarcin C, the maximal T/C% was 164 by successive administration of 0.125 mg/kg/day (day 1 -10). It also gave the prolongation of life span of mice bearing i.p. P388 leukemia (T/C 141 %) by i.p. injection for 10 days, and inhibited the growth of sarcoma 180 (T/C 42%) and Lewis lung carcinoma implanted s.c. (T/C 23 %) by i.v. administration for 6 or 7 days. It inhibited the growth of P388 leukemia cells in vitro and showed significant inhibition on the colony formation of HeLa S3 cells. DNA and RNA synthesis were more strongly inhibited than protein synthesis by trioxacarcin C. Also, it induced strand scission of PM-2 DNA without reducing agents or metals. It did not effect the number of white blood cells and blood urea nitrogen value of the peripheral blood. Mitomycin C (Kyowa Hakko Kogyo Co., Ltd., Japan), bleomycin (Nippon Kayaku Co., Ltd., Japan) and neocarzinostatin (Yamanouchi Seiyaku Co., Ltd., Japan) were used reference antitumor agents.
[ Culture of Leukemia P388 Cells Leukemia P388 cells were cultured in RPMI 1640 (Gibco Laboratories, New York, U.S.A.) supplemented with 5 % fetal bovine serum (Gibco Laboratories), 50 ,ctM of 2-mercaptoethanol , 100 U/ml of benzylpenicillin (Meiji Seika Co., Ltd., Tokyo, Japan) and 100 µg/ml of streptomycin (Kyowa Hakko Co., Ltd., Tokyo, Japan). For testing the growth inhibitory activity of drugs, 2 x 10" cells precultured for 24 hours at 37°C in a humidified atmosphere of 5 % CO. in air, were treated with drugs for 1 hour (pulse exposure) or for 72 hours (continuous exposure). The cell count were made at 72 hours after addition of drug.
Incorporation of the Labeled Precursors into Macromolecule
Logarithmically growing P388 cells (1 x 101/ml) were cultured with trioxacarcin C. [3H]Thymidine (103 mCi/mg), [3H]uridine (114 mCi/mg) or [3H]leucine (385 mCi/mg) were added at 1, 3 and 5 hours after addition of trioxacarcin C. The cells collected on membrane filter GF/F (Whatman Co., Ltd., England) were washed with cold phosphate buffered saline (pH 7.4), and rinsed with cold 5 % trichloroacetic acid several times. The radioactivity on the filter was counted by a liquid scintillation counter (Aloka LSC-653).
Culture of HeLa S3 Cells HeLa S3 cells were cultured in Eagle minimum essential medium (MEM, Nissui Seiyaku Co., Ltd., Tokyo, Japan) supplemented with 10% fetal bovine serum, 50 yg/ml of kanamycin and 292,ug/ml of L-glutamine.
For testing the lethal effect of drugs, 150 or 750 HeLa S. cells were seeded in plastic Petri dishes (60 x 15 mm, Falcon, California, U.S.A.). After incubating for 3 hours at 37°C in a humidified atmosphere of 5 % CO. in air, the cells were treated with drugs for 1 hour, rinsed with phosphate balanced saline (pH 7.4), and fed the fresh prewarmed medium. The cells were cultured for 10-i12 days for colony development, and fixed and stained with 4 % Giemsa solution for counting the number of colonies. The plating efficiency of control cells were 70 -90 % in all experiments.
Analysis of DNA Degradation in Agarose Gel Electrophoresis
The reaction mixtures contained 0.5 jig PM-2 DNA, 40 mm Tris-HCl buffer (pH 7.8) and various concentration of drug. After incubation for 30 minutes at room temperature, the reaction was terminated by addition of 5 Fcl of 50 mm EDTA. After addition of 0.1% bromophenol blue in 75% glycerol, the resultant mixture was electrophoresed on 0.8 % agarose gel according to the procedure described by SUZUKI et al.1) After electrophoresis, the gels were stained in electrophoresis buffer containing 0.5 jig/ ml of ethidium bromide.
Results

Acute Toxicity
The LDSO of trioxacarcin C was about 1.0 mg/kg by a single intraperitoneal (i.p.) or intraven (i.v.) administration in ddY mice.
Antitumor Activity Summary of the antitumor activity of trioxacarcin C against murine tumors is shown in Table 1 .
Trioxacarcin C inhibited the growth of solid sarcoma 180 by successive i.v. injection with minimal T/C of 42 on day 7. But a single injection gave only 46%. inhibition on tumor growth. The growth of Lewis lung carcinoma was inhibited by the successive i.v. treatment of trioxacarcin C with minimal T/C % of 23 on day 13. Maximal T/C % of 121 for survival day was obtained in this schedule, but prolongation of life span was not significant. markedly inhibited by trioxacarcin C in vitro. As shown in Table 2 , the IQ, (concentration which gave 50 % cell number of control) was 8.24 x 10-e mM at continuous exposure, and 1.39x 10-4 MM at pulse exposure. The ICED value of trioxacarcin C was more than 100 times lower than that of bleomycin by pulse and continuous exposure. Neocarzinostatin was more inhibitory than trioxacarcin C by pulse exposure.
Lethal
Effect on HeLa S3 Cells
The dose-survival curve of HeLa S; cells exposed to trioxacarcin C for 1 hour is presented in Fig. 1. Trioxacarcin C-treated cells showed a dose-dependent exponential survival curve with a slight shoulder at low concentration. The mean lethal dose (Do, the dose necessary to give 37Y. survival) was 1.30 x 10-D mM, and n (extrapolating value of an exponential portion of dose survival curve) was 1.60 for trioxacarcin C. For bleomycin-treated cells, the Do and n values were 1.46 10 mm and 0.69, and for neocarzinostatin, 1.32x, 10-1 mm and 3.48, respectively. (ii) The labelled precursors were added at Trioxacarcin C 3 hours after addition of trioxacarcin C and radioactivity was counted after pulse labelling for 1 hour. For solid tumors, a single administration of trioxacarcin C not inhibit the growth of solid sarcoma 180 and Lewis lung carcinoma. The successive injection (day 1-6) gave T/C % of 42 against sarcoma 180 on day 7 and all animals treated with 0.5 mg/kg/day survived on day 7. But, as mortality of treated animal was not observed thereafter, we could not conclude the effectiveness of trioxacarcin C against sarcoma 180. For solid tumor of Lewis lung carcinoma, 7 successive i.v. administrations of trioxacarcin C inhibited the growth of tumor and gave a slight prolongation of life span with TIC % of 121, showing no sign of toxic death. In the previous report, LD50 was reported to be 2 mg/kg by a single i.p. administration,' but further studies with purified sample gave 1 mg/kg for LD50 by a single injection. The discrepancy of the values between previous and this report might result from the purity of sample. 
Effect on Macromolecular Synthesis
